These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 10656425)

  • 1. Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study.
    Brewer GJ; Dick RD; Grover DK; LeClaire V; Tseng M; Wicha M; Pienta K; Redman BG; Jahan T; Sondak VK; Strawderman M; LeCarpentier G; Merajver SD
    Clin Cancer Res; 2000 Jan; 6(1):1-10. PubMed ID: 10656425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer.
    Redman BG; Esper P; Pan Q; Dunn RL; Hussain HK; Chenevert T; Brewer GJ; Merajver SD
    Clin Cancer Res; 2003 May; 9(5):1666-72. PubMed ID: 12738719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tetrathiomolybdate therapy protects against bleomycin-induced pulmonary fibrosis in mice.
    Brewer GJ; Ullenbruch MR; Dick R; Olivarez L; Phan SH
    J Lab Clin Med; 2003 Mar; 141(3):210-6. PubMed ID: 12624602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer therapy with tetrathiomolybdate: antiangiogenesis by lowering body copper--a review.
    Brewer GJ; Merajver SD
    Integr Cancer Ther; 2002 Dec; 1(4):327-37. PubMed ID: 14664727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of lowering copper levels with tetrathiomolybdate and zinc on mouse tumor and doxorubicin models.
    Hou G; Dick R; Zeng C; Brewer GJ
    Transl Res; 2006 Dec; 148(6):309-14. PubMed ID: 17162252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of key cytokines by tetrathiomolybdate in the bleomycin model of pulmonary fibrosis.
    Brewer GJ; Dick R; Ullenbruch MR; Jin H; Phan SH
    J Inorg Biochem; 2004 Dec; 98(12):2160-7. PubMed ID: 15541506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of copper suppression as an antiangiogenic strategy in head and neck squamous cell carcinoma.
    Cox C; Teknos TN; Barrios M; Brewer GJ; Dick RD; Merajver SD
    Laryngoscope; 2001 Apr; 111(4 Pt 1):696-701. PubMed ID: 11359142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II trial of tetrathiomolybdate after surgery for malignant mesothelioma: final results.
    Pass HI; Brewer GJ; Dick R; Carbone M; Merajver S
    Ann Thorac Surg; 2008 Aug; 86(2):383-9; discussion 390. PubMed ID: 18640301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor and antiinflammatory effects of tetrathiotungstate in comparison with tetrathiomolybdate.
    Hou G; Dick R; Zeng C; Brewer GJ
    Transl Res; 2007 May; 149(5):260-4. PubMed ID: 17466925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of copper depletion with tetrathiomolybdate as an antiangiogenesis strategy in patients with hormone-refractory prostate cancer.
    Henry NL; Dunn R; Merjaver S; Pan Q; Pienta KJ; Brewer G; Smith DC
    Oncology; 2006; 71(3-4):168-75. PubMed ID: 17641535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticopper therapy against cancer and diseases of inflammation and fibrosis.
    Brewer GJ
    Drug Discov Today; 2005 Aug; 10(16):1103-9. PubMed ID: 16182195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of tetrathiomolybdate in a mouse model of multiple sclerosis.
    Hou G; Abrams GD; Dick R; Brewer GJ
    Transl Res; 2008 Nov; 152(5):239-44. PubMed ID: 19010295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis.
    Pan Q; Kleer CG; van Golen KL; Irani J; Bottema KM; Bias C; De Carvalho M; Mesri EA; Robins DM; Dick RD; Brewer GJ; Merajver SD
    Cancer Res; 2002 Sep; 62(17):4854-9. PubMed ID: 12208730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tetrathiomolybdate as an antiangiogenesis therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration.
    Vine AK; Brewer GJ
    Trans Am Ophthalmol Soc; 2002; 100():73-6; discussion 76-7. PubMed ID: 12545680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zinc and tetrathiomolybdate for the treatment of Wilson's disease and the potential efficacy of anticopper therapy in a wide variety of diseases.
    Brewer GJ
    Metallomics; 2009; 1(3):199-206. PubMed ID: 21305118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease.
    Brewer GJ; Askari F; Lorincz MT; Carlson M; Schilsky M; Kluin KJ; Hedera P; Moretti P; Fink JK; Tankanow R; Dick RB; Sitterly J
    Arch Neurol; 2006 Apr; 63(4):521-7. PubMed ID: 16606763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tetrathiomolybdate, a copper chelator for the treatment of Wilson disease, pulmonary fibrosis and other indications.
    Medici V; Sturniolo GC
    IDrugs; 2008 Aug; 11(8):592-606. PubMed ID: 18683094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Copper lowering therapy with tetrathiomolybdate as an antiangiogenic strategy in cancer.
    Brewer GJ
    Curr Cancer Drug Targets; 2005 May; 5(3):195-202. PubMed ID: 15892619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anticopper efficacy of captopril and sodium dimercaptosulphonate in patients with Wilson's disease.
    Wang XP; Yang RM; Ren MS; Sun BM
    Funct Neurol; 2003; 18(3):149-53. PubMed ID: 14703896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The promise of copper lowering therapy with tetrathiomolybdate in the cure of cancer and in the treatment of inflammatory disease.
    Brewer GJ
    J Trace Elem Med Biol; 2014 Oct; 28(4):372-8. PubMed ID: 25194954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.